All lobbying filings

Cornerstone Government Affairs, Inc.

Cornerstone Government Affairs, Inc. filed a Q2 report for The United States Pharmacopeial Convention on July 13, 2026, reporting $60,000 in lobbying income.

Lobbying for The United States Pharmacopeial Convention · Pharmaceuticals

As filed: CORNERSTONE GOVERNMENT AFFAIRS, INC. for THE UNITED STATES PHARMACOPEIAL CONVENTION.

All filings by Cornerstone Government Affairs, Inc. · Everything The United States Pharmacopeial Convention has reported

Filing · LD-2 quarterly report Q2 report

Reporting period

2nd Quarter 2026

Apr 1 - June 30 · Posted Jul 13, 2026

Income

$60,000

What the client paid this registrant for the period.

Client based in

Maryland

Official filing document

Lobbyists on this filing 4

ANDREW FLICK

Previously held: Spec Asst to the Pres & Sr Adv for Cong Affairs and Strategic Outreach, Office of the VP; Exec Dir, New Democrat Coalition; Chief of Staff (Trone); Dep Chief of Staff (Moulton); Leg Director (Costa); Leg Asst (Skelton)
DIANNE NELLOR

Previously held: Clerk and Prof Staff Senate Approps Cmte; Prof. Staff Joint Econ. Cmte
ELIZABETH TEED GRIFFIN

Previously held: Legislative Assistant, House Member Office (Westerman)
MICHAEL GOODMAN

Previously held: Chief of Staff House Member Office (Kind), Legislative Staff House Member Office (Braley, Barrow)

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 3

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 4

Health Issues

Issues related to strengthening the resiliency of the U.S. medical supply chain.

Pharmacy

Issues related to strengthening the resiliency of the U.S. medical supply chain.

Medical/Disease Research/Clinical Labs

Issues related to strengthening the resiliency of the U.S. medical supply chain.

Trade (domestic/foreign)

Issues related to strengthening the resiliency of the U.S. medical supply chain.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.